Review of the impact of molecular analysis on the therapy of medulloblastoma

[1]  Jennifer L. Hadley,et al.  Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group. , 2021, JAMA oncology.

[2]  Jennifer L. Hadley,et al.  Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Merchant,et al.  Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Hawkins,et al.  MBCL-25. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES , 2020, Neuro-Oncology.

[5]  C. Sommer,et al.  Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  V. Hovestadt,et al.  Medulloblastomics revisited: biological and clinical insights from thousands of patients , 2019, Nature Reviews Cancer.

[7]  M. Souweidane,et al.  Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Claire M. Faltermeier,et al.  Survival of infants ≤24 months of age with brain tumors: A population-based study using the SEER database , 2019, PloS one.

[9]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[10]  David T. W. Jones,et al.  Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. , 2018, The Lancet. Oncology.

[11]  Roland Eils,et al.  Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort , 2018 .

[12]  D. Johnston,et al.  Survival Following Tumor Recurrence in Children With Medulloblastoma , 2018, Journal of pediatric hematology/oncology.

[13]  Charles Y. Lin,et al.  NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma. , 2018, Cancer cell.

[14]  S. Kaste,et al.  Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor , 2017, Oncotarget.

[15]  Sirintra Nakjang,et al.  Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study , 2017, The Lancet. Oncology.

[16]  A. Goldenberg,et al.  Intertumoral Heterogeneity within Medulloblastoma Subgroups. , 2017, Cancer cell.

[17]  Martin J. Aryee,et al.  OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma. , 2017, Cancer discovery.

[18]  G. Gustafsson,et al.  Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study , 2016, Journal of Neuro-Oncology.

[19]  M. Kool,et al.  Risk stratification of childhood medulloblastoma in the molecular era: the current consensus , 2016, Acta Neuropathologica.

[20]  Gary D. Bader,et al.  Divergent clonal selection dominates medulloblastoma at recurrence , 2016, Nature.

[21]  D. Mitra,et al.  SIOP PODC adapted treatment recommendations for standard‐risk medulloblastoma in low and middle income settings , 2015, Pediatric blood & cancer.

[22]  Florence I. Raynaud,et al.  Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease , 2015, Cancer cell.

[23]  Gary D Bader,et al.  Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma , 2014, Nature.

[24]  Toshihiro Kumabe,et al.  Cytogenetic prognostication within medulloblastoma subgroups. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Roland Eils,et al.  Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.

[26]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[27]  Gary D Bader,et al.  Comprehensive identification of mutational cancer driver genes across 12 tumor types , 2013, Scientific Reports.

[28]  F. Béby,et al.  The homeobox gene Otx2 in development and disease. , 2013, Experimental eye research.

[29]  Matthew J. Betts,et al.  Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.

[30]  Steven J. M. Jones,et al.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.

[31]  Jill P. Mesirov,et al.  MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.

[32]  Elaine R. Mardis,et al.  Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.

[33]  Stefan M. Pfister,et al.  The clinical implications of medulloblastoma subgroups , 2012, Nature Reviews Neurology.

[34]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.

[35]  David T. W. Jones,et al.  Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations , 2012, Cell.

[36]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[37]  S. Croul,et al.  Adult medulloblastoma comprises three major molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Arie Perry,et al.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.

[40]  Yiai Tong,et al.  Subtypes of medulloblastoma have distinct developmental origins , 2010, Nature.

[41]  Axel Benner,et al.  Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Hong Wang,et al.  PRDM6 is enriched in vascular precursors during development and inhibits endothelial cell proliferation, survival, and differentiation. , 2008, Journal of molecular and cellular cardiology.

[43]  D. Ellison,et al.  Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable Prognosis , 2006, Cell cycle.

[44]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[45]  O. McDonald,et al.  PRISM/PRDM6, a Transcriptional Repressor That Promotes the Proliferative Gene Program in Smooth Muscle Cells , 2006, Molecular and Cellular Biology.

[46]  Claire L Weston,et al.  beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Helen Baines,et al.  Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. , 2004, Cancer cell.

[48]  R. Gilbertson,et al.  Medulloblastoma: signalling a change in treatment. , 2004, The Lancet. Oncology.

[49]  A. Simeone.  Otx1 and Otx2 in the development and evolution of the mammalian brain , 1998, The EMBO journal.

[50]  C. Worster-Drought,et al.  Medulloblastoma (?) , 1931, Methods in Molecular Biology.

[51]  David Hogg,et al.  Mutations in SUFU predispose to medulloblastoma , 2002, Nature Genetics.